Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen.
It has been shown recently that BCG can be used as a live recombinant vaccine to stimulate immune responses. Proliferative or cytotoxic T-cell responses against several viral proteins such as HIV Gag, Env or Nef were obtained after parenteral immunization with BCG expressing these proteins. Antibody responses were also obtained after immunization of mice with recombinant BCG strain which expressed lac Z under the control of a promoter sequence isolated from Mycobacterium paratuberculosis. We have used this recombinant vaccine in guinea-pigs to investigate the influence of various routes of immunization on the immunogenicity of a foreign antigen expressed by recombinant BCG. Guinea-pigs were immunized by oral, respiratory or intradermal routes and proliferative responses, delayed-type hypersensitivity and antibody responses specific for beta-galactosidase were followed for 16 weeks. Results demonstrated that humoral and cellular immune responses specific for beta-galactosidase can be produced in all groups of guinea-pigs. However, the respiratory and especially the oral route of administration induced higher local and systemic immune responses than the intradermal route of immunization. Moreover, the oral immunization of mice with this recombinant BCG induced IgA responses which could be detected in both sera and intestinal secretions. Therefore, this study demonstrates for the first time that oral immunization with recombinant BCG can induce strong cellular and humoral immune responses.
Lagranderie
M
M
Laboratoire du BCG, Institut Pasteur de Paris, France.
Murray
A
A
Gicquel
B
B
Leclerc
C
C
Gheorghiu
M
M
D000280:Administration, Inhalation; D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000941:Antigens / Q000494:pharmacology*; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D004355:Drug Stability; D005260:Female; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects*; D007114:Immunization; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014018:Tissue Distribution; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D001616:beta-Galactosidase / Q000494:pharmacology
D000941:Antigens; D001500:BCG Vaccine; D014409:Tumor Necrosis Factor-alpha; D014614:Vaccines, Synthetic; D001616:beta-Galactosidase